ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Injectable Drug Delivery Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå¿¡ °üÇÑ Á¾ÇÕ º¸°í¼¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤µ¿Ç⡤±âȸ¡¤ÃËÁø¿äÀΡ¤°úÁ¦ µî Áß¿äÇÑ ½ÃÀå ¿ªÇÐÀ» öÀúÇÏ°Ô Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â 2025-2032³â ¼¼°è ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀåÀÇ ¿¹Ãø ¼ºÀå ±Ëµµ¸¦ ¼³¸íÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå ±Ô¸ð(2025³â) : 7,800¾ï ´Þ·¯
¿¹Ãø ½ÃÀå°¡Ä¡(2032³â) : 1Á¶ 4,101¾ï ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2025-2032³â) : 8.8%
ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå - Á¶»ç ¹üÀ§ :
ÁÖ»ç¿ë ¾à¹°Àü´Þ ½Ã½ºÅÛÀº ¸¸¼ºÁúȯ °ü¸®, ÀÀ±ÞÀÇ·á, ¹é½Å µîÀÇ ¾à¹° Åõ¿©¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àü´Þ ½Ã½ºÅÛ¿¡´Â ±âÁ¸ ÁÖ»ç±â, ÇÁ¸®Çʵå ÁÖ»ç±â, ÀÚµ¿ ÁÖ»ç±â, ¹«Ä§ ÁÖ»ç±â µîÀÌ ÀÖÀ¸¸ç, Á¤È®ÇÑ ¾à¹° Åõ¿©¿Í ȯÀÚ ¼øÀÀµµ Çâ»óÀ» º¸ÀåÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº º´¿ø, Ŭ¸®´Ð, ÀçÅÃÀÇ·á, ¿Ü·¡Áø·á¼¾ÅÍ µîÀ» ´ë»óÀ¸·Î Ä¡·á °á°ú¸¦ Çâ»ó½ÃŰ´Â ÷´Ü ¾à¹°Àü´Þ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, »ý¹°Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ ±â¼ú ¹ßÀü, ÀçÅÃÀÇ·á¿¡¼ ÀÚ°¡Åõ¿© ÀåºñÀÇ Ã¤Åà Áõ°¡ µîÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
¼¼°è ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀåÀº ´ç´¢º´, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ¸¸¼ºÁúȯ Ä¡·á¿¡¼ »ý¹°Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÚµ¿ ÁÖ»ç±â, ÇÁ¸®ÇÊµå ½Ã¸°Áö µî ÀÚ°¡ Åõ¾à ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±Þ¼ÓÇÑ È®´ë´Â ȯÀÚÀÇ ÆíÀǼº°ú º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤½Å°Ç° Ä¡·á ¹× ÅëÁõ °ü¸®¿¡¼ Àå½Ã°£ Áö¼ÓµÇ´Â ÁÖ»çÁ¦ÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î´Ïµé ÆÐÄ¡ ¹× ½º¸¶Æ® ÀÎÁ§ÅÍ¿Í °°Àº ±â¼úÀÇ ¹ßÀüÀº ¾à¹°ÀÇ »ýü ÀÌ¿ë·üÀ» Çâ»ó½Ã۰í ÁÖ»ç½Ã ÅëÁõÀ» °¨¼Ò½ÃÅ´À¸·Î½á ¾÷°è¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ƯÈ÷ °¨¿°¼º Áúȯ ¹× ¼Ò¾Æ ¿¹¹æÁ¢Á¾ µî Àü ¼¼°è ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ È®´ë´Â ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:
ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀåÀº ³ôÀº ¼ºÀå¼¼°¡ ¿¹»óµÇÁö¸¸, ³ôÀº Á¦Á¶ ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç, ÁÖ»çħ ÀÚ»ó »ç°í¿¡ ´ëÇÑ ¿ì·Á µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. »ý¹°Á¦Á¦ÀÇ Á¦ÇüÈ ¹× ¾ÈÁ¤¼º¿¡ µû¸¥ º¹À⼺Àº Á¾Á¾ °³¹ß ¹× Á¦Á¶ ºñ¿ëÀÇ »ó½ÂÀ» ÃÊ·¡ÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ»ç±â ¹× ¾àǰÀÇ ÀûÇÕ¼º¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦´Â ½ÅÁ¦Ç° ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. °¨¿°ÀÇ À§Çè°ú »ç¿ëÇÑ ÁÖ»ç±âÀÇ ºÎÀûÀýÇÑ Æó±â µî ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á´Â ÁÖ»ç¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â ±â¼ú °³¹ß ¹× Æó±â ¹æ¹ýÀÇ °³¼±ÀÌ ¿ä±¸µÇ´Â ¶Ç ´Ù¸¥ °úÁ¦ÀÔ´Ï´Ù.
½ÃÀå ±âȸ:
ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀåÀº ¾à¹° Á¦Çü°ú Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ Çõ½ÅÀ¸·Î ÀÎÇØ Å« ºñÁî´Ï½º ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¾à¹°Àü´ÞÀ» À§ÇÑ ¿þ¾î·¯ºí ÁÖ»ç±âÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¿ë·® ÃßÀû ¹× ¿ø°Ý ¸ð´ÏÅ͸µÀ» À§ÇÑ ½º¸¶Æ® ±â¼úÀÇ ÅëÇÕÀÌ ½ÃÀåÀ» º¯È½Ã۰í ÀÖ½À´Ï´Ù. Á¾¾çÇÐ ¹× ¸é¿ª ¿ä¹ý ºÐ¾ß¿¡¼ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â À¯¸®ÇÑ ¼ºÀå °æ·Î¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥ ¹× ÀÚ°¡ Åõ¾à ¾à¹° ¿ä¹ýÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ±¸»óÀº »õ·Î¿î ½ÃÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç¿Í ÀÇ·á±â±â Á¦Á¶¾÷üÀÇ Àü·«Àû Á¦ÈÞ´Â Â÷¼¼´ë ÁÖ»çÁ¦ °³¹ßÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
Á¦¾à¾÷°è¿¡¼ °¢±¤¹Þ°í ÀÖ´Â ¾à¹°Àü´Þ ½Ã½ºÅÛÀº?
±â¼ú ¹ßÀüÀº ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô º¯È½Ã۰í Àִ°¡?
½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾îµð¿¡ ÀÖÀ¸¸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è ÁÖ»çÁ¦ ¾à¹°Àü´Þ ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
±ÔÁ¦ »óȲ
Á¦Ç° äÅà ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
ÁÖ¿ä °Å·¡¿Í ÇÕº´
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ëÀû ¸ÅÃâ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, 2019-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, 2025-2032³â
¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : Á¦Ç°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Á¦Ç°º°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Á¦Ç°º°, 2025-2032³â
ÀÚ±â ÁÖ»ç±â
½Ì±Û è¹ö ÀÚ±â ÁÖ»ç±â
µà¾ó è¹ö ÀÚ±â ÁÖ»ç±â
¹«¹Ù´Ã ÁÖ»ç±â
ÇÁ¸®ÇÊµå ¹«¹Ù´Ã ÁÖ»ç±â
ÃæÀü °¡´ÉÇÑ ¹«¹Ù´Ã ÁÖ»ç±â
ÀÚµ¿ ÁÖ»ç±â
ÇÁ¸®Çʵå ÀÚµ¿ ÁÖ»ç±â
ÃæÀü °¡´ÉÇÑ ÀÚµ¿ ÁÖ»ç±â
¿þ¾î·¯ºí ÁÖ»ç±â
¿þ¾î·¯ºí ÆÐÄ¡ ÁÖ»ç±â
ü¿Ü ÀåÂøÇü ÁÖ»ç±â
Àν¶¸° Ææ
Àç»ç¿ë °¡´É Àν¶¸° Ææ
ÀÏȸ¿ë Àν¶¸° Ææ
½º¸¶Æ® Àν¶¸° Ææ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Á¦Ç°
¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : Å×Å©³î·¯Áö
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Å×Å©³î·¯Áöº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Å×Å©³î·¯Áöº°, 2025-2032³â
ºñ½º¸¶Æ® ÁÖ»ç±â
½º¸¶Æ® ÁÖ»ç±â
ÀΰøÁö´É(AI)°ú ±â°èÇнÀÀÇ ÅëÇÕ
±Ù°Å¸® ¹«¼±Åë½Å(NFC)
Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ
Bluetooth
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Å×Å©³î·¯Áö
¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : »ç¿ë »óȲ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, »ç¿ë »óȲº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, »ç¿ë »óȲº°, 2025-2032³â
ÀÏȸ¿ë ÁÖ»ç±â
Àç»ç¿ë °¡´ÉÁÖ»ç±â
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : »ç¿ë »óȲ
¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : ÀûÀÀÁõ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, ÀûÀÀÁõº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, ÀûÀÀÁõº°, 2025-2032³â
¾Æ³ªÇʶô½Ã½º
´ç´¢º´
½ÉÇ÷°üÁúȯ
´Ù¹ß¼º °æÈÁõ
·ù¸¶Æ¼½º °üÀý¿°
¾Ï
¿Ü»ó°ú ÀÀ±Þ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÀûÀÀÁõ
¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : À¯Åë ä³Î
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, À¯Åë ä³Îº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, À¯Åë ä³Îº°, 2025-2032³â
º´¿ø ¾à±¹
µå·¯±×½ºÅä¾î
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : À¯Åë ä³Î
Á¦5Àå ¼¼°èÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®, Áö¿ªº°, 2019-2023³â¡¡
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025-2032³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦7Àå À¯·´ÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦9Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÁÖ»ç¿ë ¾à¹°Àü´Þ ½ÃÀå Àü¸Á
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
½ÃÀå ±¸Á¶
½ÃÀ庰 °æÀï °ÝÈ ¸Ê
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Eli Lilly and Company
Biocon
Becton, Dickinson &Company
West Pharmaceutical Services, Inc.
Johnson &Johnson
Antares Pharma
AbbVie Inc.
Pfizer Inc.
Mylan NV
Vetter Pharma-Fertigung GmbH &Co.KG
Emperra GmbH
Digital Medics Pty Ltd
Enable Injections LLC
Insulet corporation
Consort Medical Plc.
Diabnext
Diamesco Co., Ltd
SCHOTT AG(Schott Kaisha Pvt. Ltd.)
SiO2 Medical Products
Integrity Bio, Inc.
Wilhelm Haselmeier GmbH &Co. KG
Tandem Diabetes Care
Sanofi SA
Companion Medical Inc.
Ypsomed
F. Hoffman-La Roche Ltd.
Novo Nordisk A/S
Medtronic Plc.
Á¦13Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»çÀÇ ÀüÁ¦
µÎÀÚ¾î¿Í ¾à¾î
KSA
Persistence Market Research has recently released a comprehensive report on the worldwide market for injectable drug delivery. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global injectable drug delivery market from 2025 to 2032.
Key Insights:
Injectable Drug Delivery Market Size (2025E): US$ 780 Bn
Projected Market Value (2032F): US$ 1410.1 Bn
Global Market Growth Rate (CAGR 2025 to 2032): 8.8%
Injectable Drug Delivery Market - Report Scope:
Injectable drug delivery systems are critical for the administration of medications in chronic disease management, emergency medicine, and vaccines. These delivery systems include conventional syringes, prefilled syringes, autoinjectors, and needle-free injectors, which ensure precise drug dosing and improved patient compliance. The market caters to hospitals, clinics, home healthcare, and ambulatory care centers, offering advanced drug delivery solutions that enhance therapeutic outcomes. Market growth is driven by the rising prevalence of chronic diseases, technological advancements in biologics and biosimilars, and the increasing adoption of self-administration devices for home care.
Market Growth Drivers:
The global injectable drug delivery market is propelled by several key factors, including the growing demand for biologics and biosimilars in treating chronic diseases such as diabetes, cancer, and autoimmune disorders. The rapid expansion of self-administration drug delivery systems, such as autoinjectors and prefilled syringes, is enhancing patient convenience and compliance. Furthermore, the increasing use of long-acting injectables in mental health treatment and pain management is contributing to market growth. Technological advancements, such as microneedle patches and smart injectors, are revolutionizing the industry by improving drug bioavailability and reducing injection pain. The expansion of vaccination programs worldwide, particularly for infectious diseases and pediatric immunizations, further accelerates market expansion.
Market Restraints:
Despite strong growth prospects, the injectable drug delivery market faces challenges, including high production costs, stringent regulatory requirements, and concerns regarding needle-stick injuries. The complexities associated with biologic drug formulation and stability often result in increased development and manufacturing costs. Additionally, strict regulations governing injectable devices and drug compatibility can delay market entry for new products. Safety concerns, including the risk of infections and improper disposal of used injectables, pose further challenges, necessitating the development of needle-free technologies and improved disposal mechanisms.
Market Opportunities:
The injectable drug delivery market presents significant opportunities driven by innovation in drug formulations and delivery mechanisms. The increasing adoption of wearable injectors for continuous drug delivery and the integration of smart technology for dose tracking and remote monitoring are transforming the market. The rising demand for biosimilars and biologics in oncology and immunotherapy presents a lucrative growth avenue. Additionally, government initiatives promoting vaccination programs and self-administration drug therapies create new market opportunities. Strategic collaborations between pharmaceutical companies and medical device manufacturers are expected to drive the development of next-generation injectable solutions.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the injectable drug delivery market globally?
Which drug delivery systems are gaining prominence in the pharmaceutical industry?
How are technological advancements reshaping the competitive landscape of the injectable drug delivery market?
Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global injectable drug delivery market?
Competitive Intelligence and Business Strategy:
Leading players in the global injectable drug delivery market, including Becton, Dickinson and Company, Gerresheimer AG, Eli Lilly and Company, and Pfizer Inc., are focusing on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in research and development to introduce advanced delivery solutions such as needle-free injectors, smart syringes, and biodegradable drug delivery systems. Collaborations with biotech firms and regulatory agencies facilitate market access and regulatory compliance. Moreover, emphasis on patient-centric drug delivery systems, safety enhancements, and sustainability initiatives is shaping the future of the market.
Key Companies Profiled:
Becton, Dickinson and Company
Gerresheimer AG
Eli Lilly and Company
Pfizer Inc.
Ypsomed AG
West Pharmaceutical Services, Inc.
Schott AG
Novo Nordisk A/S
Terumo Corporation
Baxter International Inc.
Injectable Drug Delivery Market Segmentation
By Product
Self-injectors
Needle Free Injectors
Auto Injectors
Wearable Injectors
By Technology
Non-smart Injectors
Smart Injectors
By Usage
By Indication
Anaphylaxis
Diabetes
Cardiovascular Diseases
Multiple Sclerosis
Rheumatoid Arthritis
Cancer
Trauma and Emergency
By Distribution Channel
Hospital Pharmacies
Drug Stores
Online Pharmacies
Retail Pharmacies
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Global Injectable Drug Delivery Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis
4. Global Injectable Drug Delivery Market Outlook
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Injectable Drug Delivery Market Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
4.3.3.1. Self-Injectors
4.3.3.1.1. Single Chamber Self Injectors
4.3.3.1.2. Dual Chamber Self Injectors
4.3.3.2. Needle Free Injectors
4.3.3.2.1. Pre-filled Needle Free Injectors
4.3.3.2.2. Fill-able Needle free Injectors
4.3.3.3. Auto Injectors
4.3.3.3.1. Prefilled Auto Injectors
4.3.3.3.2. Fill-Able Auto Injectors
4.3.3.4. Wearable Injectors
4.3.3.4.1. Wearable Patch Injectors
4.3.3.4.2. Off-body Worn Injectors
4.3.3.5. Insulin Pens
4.3.3.5.1. Reusable Insulin Pens
4.3.3.5.2. Disposable Insulin Pens
4.3.3.5.3. Smart Insulin Pens
4.3.4. Market Attractiveness Analysis: Product
4.4. Global Injectable Drug Delivery Market Outlook: Technology
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019 - 2023
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
4.4.3.1. Non-Smart Injectors
4.4.3.2. Smart Injectors
4.4.3.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
4.4.3.2.2. Near Filed Communication (NFC)
4.4.3.2.3. Cloud Computing
4.4.3.2.4. Bluetooth
4.4.4. Market Attractiveness Analysis: Technology
4.5. Global Injectable Drug Delivery Market Outlook: Usage
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Usage, 2019 - 2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
4.5.3.1. Disposable Injectors
4.5.3.2. Reusable Injectors
4.5.4. Market Attractiveness Analysis: Usage
4.6. Global Injectable Drug Delivery Market Outlook: Indication
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019 - 2023
4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
4.6.3.1. Anaphylaxis
4.6.3.2. Diabetes
4.6.3.3. Cardiovascular Diseases
4.6.3.4. Multiple Sclerosis
4.6.3.5. Rheumatoid Arthritis
4.6.3.6. Cancer
4.6.3.7. Trauma and Emergency
4.6.3.8. Others
4.6.4. Market Attractiveness Analysis: Indication
4.7. Global Injectable Drug Delivery Market Outlook: Distribution Channel
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 - 2023
4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
4.7.3.1. Hospital Pharmacies
4.7.3.2. Drug Stores
4.7.3.3. Retail Pharmacies
4.7.3.4. Online Pharmacies
4.7.4. Market Attractiveness Analysis: Distribution Channel
5. Global Injectable Drug Delivery Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Injectable Drug Delivery Market Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
6.2.1. By Country
6.2.2. By Product
6.2.3. By Technology
6.2.4. By Usage
6.2.5. By Indication
6.2.6. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
6.4.1. Self-Injectors
6.4.1.1. Single Chamber Self Injectors
6.4.1.2. Dual Chamber Self Injectors
6.4.2. Needle Free Injectors
6.4.2.1. Pre Filled Needle Free Injectors
6.4.2.2. Fill-Able Needle free Injectors
6.4.3. Auto Injectors
6.4.3.1. Prefilled Auto Injectors
6.4.3.2. Fill-Able Auto Injectors
6.4.4. Wearable Injectors
6.4.4.1. Wearable Patch Injectors
6.4.4.2. Off-body Worn Injectors
6.4.5. Insulin Pens
6.4.5.1. Reusable Insulin Pens
6.4.5.2. Disposable Insulin Pens
6.4.5.3. Smart Insulin Pens
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
6.5.1. Non-Smart Injectors
6.5.2. Smart Injectors
6.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
6.5.2.2. Near Filed Communication (NFC)
6.5.2.3. Cloud Computing
6.5.2.4. Bluetooth
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
6.6.1. Disposable Injectors
6.6.2. Reusable Injectors
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
6.7.1. Anaphylaxis
6.7.2. Diabetes
6.7.3. Cardiovascular Diseases
6.7.4. Multiple Sclerosis
6.7.5. Rheumatoid Arthritis
6.7.6. Cancer
6.7.7. Trauma and Emergency
6.7.8. Others
6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
6.8.1. Hospital Pharmacies
6.8.2. Drug Stores
6.8.3. Retail Pharmacies
6.8.4. Online Pharmacies
6.9. Market Attractiveness Analysis
7. Europe Injectable Drug Delivery Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
7.2.1. By Country
7.2.2. By Product
7.2.3. By Technology
7.2.4. By Usage
7.2.5. By Indication
7.2.6. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
7.4.1. Self-Injectors
7.4.1.1. Single Chamber Self Injectors
7.4.1.2. Dual Chamber Self Injectors
7.4.2. Needle Free Injectors
7.4.2.1. Pre Filled Needle Free Injectors
7.4.2.2. Fill-Able Needle free Injectors
7.4.3. Auto Injectors
7.4.3.1. Prefilled Auto Injectors
7.4.3.2. Fill-Able Auto Injectors
7.4.4. Wearable Injectors
7.4.4.1. Wearable Patch Injectors
7.4.4.2. Off-body Worn Injectors
7.4.5. Insulin Pens
7.4.5.1. Reusable Insulin Pens
7.4.5.2. Disposable Insulin Pens
7.4.5.3. Smart Insulin Pens
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
7.5.1. Non-Smart Injectors
7.5.2. Smart Injectors
7.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
7.5.2.2. Near Filed Communication (NFC)
7.5.2.3. Cloud Computing
7.5.2.4. Bluetooth
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
7.6.1. Disposable Injectors
7.6.2. Reusable Injectors
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
7.7.1. Anaphylaxis
7.7.2. Diabetes
7.7.3. Cardiovascular Diseases
7.7.4. Multiple Sclerosis
7.7.5. Rheumatoid Arthritis
7.7.6. Cancer
7.7.7. Trauma and Emergency
7.7.8. Others
7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
7.8.1. Hospital Pharmacies
7.8.2. Drug Stores
7.8.3. Retail Pharmacies
7.8.4. Online Pharmacies
7.9. Market Attractiveness Analysis
8. East Asia Injectable Drug Delivery Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
8.2.1. By Country
8.2.2. By Product
8.2.3. By Technology
8.2.4. By Usage
8.2.5. By Indication
8.2.6. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
8.4.1. Self-Injectors
8.4.1.1. Single Chamber Self Injectors
8.4.1.2. Dual Chamber Self Injectors
8.4.2. Needle Free Injectors
8.4.2.1. Pre Filled Needle Free Injectors
8.4.2.2. Fill-Able Needle free Injectors
8.4.3. Auto Injectors
8.4.3.1. Prefilled Auto Injectors
8.4.3.2. Fill-Able Auto Injectors
8.4.4. Wearable Injectors
8.4.4.1. Wearable Patch Injectors
8.4.4.2. Off-body Worn Injectors
8.4.5. Insulin Pens
8.4.5.1. Reusable Insulin Pens
8.4.5.2. Disposable Insulin Pens
8.4.5.3. Smart Insulin Pens
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
8.5.1. Non-Smart Injectors
8.5.2. Smart Injectors
8.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
8.5.2.2. Near Filed Communication (NFC)
8.5.2.3. Cloud Computing
8.5.2.4. Bluetooth
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
8.6.1. Disposable Injectors
8.6.2. Reusable Injectors
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
8.7.1. Anaphylaxis
8.7.2. Diabetes
8.7.3. Cardiovascular Diseases
8.7.4. Multiple Sclerosis
8.7.5. Rheumatoid Arthritis
8.7.6. Cancer
8.7.7. Trauma and Emergency
8.7.8. Others
8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
8.8.1. Hospital Pharmacies
8.8.2. Drug Stores
8.8.3. Retail Pharmacies
8.8.4. Online Pharmacies
8.9. Market Attractiveness Analysis
9. South Asia & Oceania Injectable Drug Delivery Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
9.2.1. By Country
9.2.2. By Product
9.2.3. By Technology
9.2.4. By Usage
9.2.5. By Indication
9.2.6. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
9.4.1. Self-Injectors
9.4.1.1. Single Chamber Self Injectors
9.4.1.2. Dual Chamber Self Injectors
9.4.2. Needle Free Injectors
9.4.2.1. Pre Filled Needle Free Injectors
9.4.2.2. Fill-Able Needle free Injectors
9.4.3. Auto Injectors
9.4.3.1. Prefilled Auto Injectors
9.4.3.2. Fill-Able Auto Injectors
9.4.4. Wearable Injectors
9.4.4.1. Wearable Patch Injectors
9.4.4.2. Off-body Worn Injectors
9.4.5. Insulin Pens
9.4.5.1. Reusable Insulin Pens
9.4.5.2. Disposable Insulin Pens
9.4.5.3. Smart Insulin Pens
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
9.5.1. Non-Smart Injectors
9.5.2. Smart Injectors
9.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
9.5.2.2. Near Filed Communication (NFC)
9.5.2.3. Cloud Computing
9.5.2.4. Bluetooth
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
9.6.1. Disposable Injectors
9.6.2. Reusable Injectors
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
9.7.1. Anaphylaxis
9.7.2. Diabetes
9.7.3. Cardiovascular Diseases
9.7.4. Multiple Sclerosis
9.7.5. Rheumatoid Arthritis
9.7.6. Cancer
9.7.7. Trauma and Emergency
9.7.8. Others
9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
9.8.1. Hospital Pharmacies
9.8.2. Drug Stores
9.8.3. Retail Pharmacies
9.8.4. Online Pharmacies
9.9. Market Attractiveness Analysis
10. Latin America Injectable Drug Delivery Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
10.2.1. By Country
10.2.2. By Product
10.2.3. By Technology
10.2.4. By Usage
10.2.5. By Indication
10.2.6. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
10.4.1. Self-Injectors
10.4.1.1. Single Chamber Self Injectors
10.4.1.2. Dual Chamber Self Injectors
10.4.2. Needle Free Injectors
10.4.2.1. Pre Filled Needle Free Injectors
10.4.2.2. Fill-Able Needle free Injectors
10.4.3. Auto Injectors
10.4.3.1. Prefilled Auto Injectors
10.4.3.2. Fill-Able Auto Injectors
10.4.4. Wearable Injectors
10.4.4.1. Wearable Patch Injectors
10.4.4.2. Off-body Worn Injectors
10.4.5. Insulin Pens
10.4.5.1. Reusable Insulin Pens
10.4.5.2. Disposable Insulin Pens
10.4.5.3. Smart Insulin Pens
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
10.5.1. Non-Smart Injectors
10.5.2. Smart Injectors
10.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
10.5.2.2. Near Filed Communication (NFC)
10.5.2.3. Cloud Computing
10.5.2.4. Bluetooth
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
10.6.1. Disposable Injectors
10.6.2. Reusable Injectors
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
10.7.1. Anaphylaxis
10.7.2. Diabetes
10.7.3. Cardiovascular Diseases
10.7.4. Multiple Sclerosis
10.7.5. Rheumatoid Arthritis
10.7.6. Cancer
10.7.7. Trauma and Emergency
10.7.8. Others
10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
10.8.1. Hospital Pharmacies
10.8.2. Drug Stores
10.8.3. Retail Pharmacies
10.8.4. Online Pharmacies
10.9. Market Attractiveness Analysis
11. Middle East & Africa Injectable Drug Delivery Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
11.2.1. By Country
11.2.2. By Product
11.2.3. By Technology
11.2.4. By Usage
11.2.5. By Indication
11.2.6. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025 - 2032
11.4.1. Self-Injectors
11.4.1.1. Single Chamber Self Injectors
11.4.1.2. Dual Chamber Self Injectors
11.4.2. Needle Free Injectors
11.4.2.1. Pre Filled Needle Free Injectors
11.4.2.2. Fill-Able Needle free Injectors
11.4.3. Auto Injectors
11.4.3.1. Prefilled Auto Injectors
11.4.3.2. Fill-Able Auto Injectors
11.4.4. Wearable Injectors
11.4.4.1. Wearable Patch Injectors
11.4.4.2. Off-body Worn Injectors
11.4.5. Insulin Pens
11.4.5.1. Reusable Insulin Pens
11.4.5.2. Disposable Insulin Pens
11.4.5.3. Smart Insulin Pens
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025 - 2032
11.5.1. Non-Smart Injectors
11.5.2. Smart Injectors
11.5.2.1. Artificial Intelligence (AI) and Machine Learning Integrated
11.5.2.2. Near Filed Communication (NFC)
11.5.2.3. Cloud Computing
11.5.2.4. Bluetooth
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Usage, 2025 - 2032
11.6.1. Disposable Injectors
11.6.2. Reusable Injectors
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025 - 2032
11.7.1. Anaphylaxis
11.7.2. Diabetes
11.7.3. Cardiovascular Diseases
11.7.4. Multiple Sclerosis
11.7.5. Rheumatoid Arthritis
11.7.6. Cancer
11.7.7. Trauma and Emergency
11.7.8. Others
11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
11.8.1. Hospital Pharmacies
11.8.2. Drug Stores
11.8.3. Retail Pharmacies
11.8.4. Online Pharmacies
11.9. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Eli Lilly and Company
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Biocon
12.3.3. Becton, Dickinson & Company
12.3.4. West Pharmaceutical Services, Inc.
12.3.5. Johnson & Johnson
12.3.6. Antares Pharma
12.3.7. AbbVie Inc.
12.3.8. Pfizer Inc.
12.3.9. Mylan N.V.
12.3.10. Vetter Pharma-Fertigung GmbH & Co.KG
12.3.11. Emperra GmbH
12.3.12. Digital Medics Pty Ltd
12.3.13. Enable Injections LLC
12.3.14. Insulet corporation
12.3.15. Consort Medical Plc.
12.3.16. Diabnext
12.3.17. Diamesco Co., Ltd
12.3.18. SCHOTT AG (Schott Kaisha Pvt. Ltd.)
12.3.19. SiO2 Medical Products
12.3.20. Integrity Bio, Inc.
12.3.21. Wilhelm Haselmeier GmbH & Co. KG
12.3.22. Tandem Diabetes Care
12.3.23. Sanofi S.A.
12.3.24. Companion Medical Inc.
12.3.25. Ypsomed
12.3.26. F. Hoffman - La Roche Ltd.
12.3.27. Novo Nordisk A/S
12.3.28. Medtronic Plc.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations